跳至主要内容
临床试验/NCT01164592
NCT01164592已完成4 期

SERVE-HF: Substudy on the Mechanistic Plausibility of the Clinical Benefits of Adaptive Servo-ventilation

ResMed188 个研究点 分布在 5 个国家目标入组 312 人开始时间: 2012年8月最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
ResMed
入组人数
312
试验地点
188
主要终点
Change in Left Ventricular Ejection Fraction (LVEF) from baseline to 12 months of therapy as measured by echocardiography (Echo).

研究概览

简要总结

The purpose of this study is to assess changes in left ventricular performance using echocardiography as well as ventricular remodelling, changes in sleep and changes in mood, anxiety and cognitive functions occurring as a result of treatment of predominant central sleep apnoea by adaptive servoventilation (ASV) in chronic heart failure in addition to optimal medical therapy in chronic heart failure. This will be a substudy of the SERVE-HF study.

详细描述

This substudy is performed within the SERVE-HF Study, a randomised, multi-centre,international trial with parallel group design, with patients randomised to either control (optimal medical management) or active treatment (optimal medical treatment plus use of adaptive servoventilation) in a 1:1 ratio. The randomization will be the same as in the parent study. For this purpose, the randomization of the parent study will be stratified as to whether a patient is included in the substudy or not. 300 patients will be recruited for the substudy overall.

For the purpose of this substudy, patients will be followed up for a period of 12 months.

The following extra tests will be performed at the baseline visit, the 3 months follow up and the 12 months follow up:

  • Echocardiogram (for both groups)
  • cMRI (for both groups)
  • PSG (at the baseline visit only for patients in the treatment group and at 3 months follow up and the 12 months follow up for all patients)
  • 4 questionnaires (for both groups)
  • Additional blood testing (for both groups)

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Change in Left Ventricular Ejection Fraction (LVEF) from baseline to 12 months of therapy as measured by echocardiography (Echo).

时间窗: Baseline (Randomization), 6- and 12 month-Follow-up-visit

次要结局

  • Changes in sleep-disordered breathing(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
  • Changes in left and right ventricular function(Baseline (Randomization), 6-and 12-month-Follow-up visit)
  • Changes in LV systolic and diastolic indexed volumes(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
  • Changes in right ventricular (RV) systolic and diastolic indexed volumes(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
  • Changes in LV and RV mass(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
  • Changes in LV sphericity index and LV end-systolic global wall stress(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
  • Changes in sleep duration and sleep stages as well as arousals(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
  • Changes in quality of life assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ)(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
  • Changes in mental status assessed by Mini-Mental State Examination (MMSE)(Baseline (Randomization), 6- and 12-month-Follow-up-visit)
  • Changes in Patient Health Questionnaire-9 (PHQ-9) score and Patient Anxiety Questionnaire GAD-7(Baseline (Randomization), 6- and 12-month-Follow-up-visit)

研究者

发起方
ResMed
申办方类型
Industry
责任方
Sponsor

研究点 (188)

Loading locations...

相似试验